These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8657645)

  • 21. A case of renal sarcoidosis with complement activation via the lectin pathway.
    Hagiwara S; Ohi H; Eishi Y; Kodama F; Tashiro K; Makita Y; Suzuki Y; Maeda K; Fukui M; Horikoshi S; Tomino Y
    Am J Kidney Dis; 2005 Mar; 45(3):580-7. PubMed ID: 15754281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesangial proliferative glomerulonephritis triggered by spleno-renal shunt in a cirrhotic patient.
    Rana SS; Das K; Mukhopadhyay S; Dinda AK; Kar P
    J Assoc Physicians India; 2002 Feb; 50():266-7. PubMed ID: 12038661
    [No Abstract]   [Full Text] [Related]  

  • 23. Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats.
    Wu SH; Wu XH; Liao PY; Dong L
    Prostaglandins Leukot Essent Fatty Acids; 2007 Mar; 76(3):173-80. PubMed ID: 17329090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesangial proliferative glomerulonephritis with deposits of anti-nicotinic acetylcholine receptor antibody in a patient with myasthenia gravis.
    Mitsui T; Okada K; Kuhara T; Hashizume T; Okazaki S; Kawajiri M; Matsumoto T
    J Clin Neurosci; 2001 Sep; 8(5):454-6. PubMed ID: 11535018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in interleukin-6 therapy].
    Ogata A; Nishimoto N; Yoshizaki K
    Rinsho Byori; 1999 Apr; 47(4):321-6. PubMed ID: 10340005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interleukin 6 (IL-6)--clinical significance].
    Kamińska B; Gradowska L; Paczek L
    Pol Arch Med Wewn; 1996 Mar; 95(3):270-6. PubMed ID: 8755859
    [No Abstract]   [Full Text] [Related]  

  • 27. Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice.
    Katsume A; Miyai T; Suzuki H; Moriguchi Y; Kawata H; Tatsumi T; Suematsu S; Kishimoto T; Ohsugi Y
    Clin Immunol Immunopathol; 1997 Feb; 82(2):117-24. PubMed ID: 9000479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrarenal infusion of supernatant from cytokine-activated human mesangial cells may cause glomerular damage.
    Chen WP; Tan SK; Chen A; Lin CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):657-65. PubMed ID: 10533294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary sediment features in proliferative and non-proliferative glomerular diseases.
    Fogazzi GB; Saglimbeni L; Banfi G; Cantú M; Moroni G; Garigali G; Cesana BM
    J Nephrol; 2005; 18(6):703-10. PubMed ID: 16358228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin-binding EGF-like growth factor is expressed by mesangial cells and is involved in mesangial proliferation in glomerulonephritis.
    Takemura T; Murata Y; Hino S; Okada M; Yanagida H; Ikeda M; Yoshioka K
    J Pathol; 1999 Nov; 189(3):431-8. PubMed ID: 10547607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical implications of DNA-topoisomerases examination in renal biopsies from patients with nephritis].
    Ivanova LV; Shilov EM; Ivanov AA; Kozlovskaia LV; Rudolph P; Proppe D
    Ter Arkh; 2003; 75(6):11-7. PubMed ID: 12920952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.
    Sansonno D; Gesualdo L; Manno C; Schena FP; Dammacco F
    Hepatology; 1997 May; 25(5):1237-44. PubMed ID: 9141444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits without Conspicuous Mesangial Proliferation, Complicated with Squamous Cell Lung Carcinoma.
    Higashihara T; Okada A; Nakamura Y; Saigusa H; Homma S; Matsumura M; Kusano T; Shimizu A; Takano H
    Intern Med; 2020 Feb; 59(4):557-562. PubMed ID: 31611527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases.
    Egido J; Gómez-Chiarri M; Ortíz A; Bustos C; Alonso J; Gómez-Guerrero C; Gómez-Garre D; López-Armada MJ; Plaza J; Gonzalez E
    Kidney Int Suppl; 1993 Jan; 39():S59-64. PubMed ID: 8385721
    [No Abstract]   [Full Text] [Related]  

  • 35. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6.
    Lui SL; Chan KW; Li FK; Cheng IK; Chan TM
    Nephron; 1998; 78(3):323-7. PubMed ID: 9546694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytokines and diseases. Abnormal expression of interleukin 6 and diseases].
    Hirano T
    Nihon Naika Gakkai Zasshi; 1991 Sep; 80(9):1401-8. PubMed ID: 1761919
    [No Abstract]   [Full Text] [Related]  

  • 37. [Progressive renal diseases: recent advances in diagnosis and treatments. Topics: II. Pathophysiology and treatments; 6. Membranoproliferative glomerulonephritis].
    Goto S; Narita I
    Nihon Naika Gakkai Zasshi; 2013 May; 102(5):1145-51. PubMed ID: 23847979
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of thrombin in mesangial proliferative glomerulonephritis.
    Kitamoto Y; Imamura T; Fukui H; Tomita K
    Kidney Int; 1998 Nov; 54(5):1767-8. PubMed ID: 9844159
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukin-6 and its relation to inflammation and disease.
    Hirano T
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S60-5. PubMed ID: 1728989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further functions of IL-6.
    Hopkins SJ; Rothwell NJ
    Immunol Today; 1991 May; 12(5):170. PubMed ID: 1750926
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.